- Home
- APLS vs TMDX Comparison
APLS vs TMDX Comparison
Compare APLS & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLS
- TMDX
- Stock Information
- Founded
- APLS 2009
- TMDX 1998
- Country
- APLS United States
- TMDX United States
- Employees
- APLS N/A
- TMDX N/A
- Industry
- APLS Biotechnology: Pharmaceutical Preparations
- TMDX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- APLS Health Care
- TMDX Health Care
- Exchange
- APLS Nasdaq
- TMDX Nasdaq
- Market Cap
- APLS 4.4B
- TMDX 4.7B
- IPO Year
- APLS 2017
- TMDX 2019
- Fundamental
- Price
- APLS $32.51
- TMDX $163.07
- Analyst Decision
- APLS Buy
- TMDX Buy
- Analyst Count
- APLS 16
- TMDX 10
- Target Price
- APLS $69.25
- TMDX $154.70
- AVG Volume (30 Days)
- APLS 1.4M
- TMDX 825.8K
- Earning Date
- APLS 10-30-2024
- TMDX 11-04-2024
- Dividend Yield
- APLS N/A
- TMDX N/A
- EPS Growth
- APLS N/A
- TMDX N/A
- EPS
- APLS N/A
- TMDX 0.09
- Revenue
- APLS $628,786,000.00
- TMDX $358,759,000.00
- Revenue This Year
- APLS $104.39
- TMDX $87.49
- Revenue Next Year
- APLS $31.39
- TMDX $30.37
- P/E Ratio
- APLS N/A
- TMDX $1,841.63
- Revenue Growth
- APLS 240.74
- TMDX 137.47
- 52 Week Low
- APLS $31.00
- TMDX $36.42
- 52 Week High
- APLS $73.80
- TMDX $177.37
- Technical
- Relative Strength Index (RSI)
- APLS 33.62
- TMDX 60.12
- Support Level
- APLS $35.16
- TMDX $133.36
- Resistance Level
- APLS $37.84
- TMDX $157.22
- Average True Range (ATR)
- APLS 2.07
- TMDX 7.67
- MACD
- APLS -0.58
- TMDX 1.56
- Stochastic Oscillator
- APLS 13.80
- TMDX 99.60
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
About TMDX TransMedics Group Inc.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.